Condition
Non Metastatic Breast Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 2 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07326800Not ApplicableRecruitingPrimary
Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cancer.
NCT01220076Phase 2CompletedPrimary
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
NCT02901223Not ApplicableCompletedPrimary
The Impact of Oncoplastic Breast Surgery on the Oncological Safety and Patient Satisfaction
NCT01563588Not ApplicableTerminatedPrimary
Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy
Showing all 4 trials